Smith & Nephew PLC ADR (SNN): Price and Financial Metrics
SNN Price/Volume Stats
Current price | $30.08 | 52-week high | $33.08 |
Prev. close | $30.29 | 52-week low | $21.77 |
Day low | $29.90 | Volume | 505,000 |
Day high | $30.26 | Avg. volume | 850,232 |
50-day MA | $30.59 | Dividend yield | 2.99% |
200-day MA | $27.31 | Market Cap | 13.14B |
SNN Stock Price Chart Interactive Chart >
SNN POWR Grades
- Sentiment is the dimension where SNN ranks best; there it ranks ahead of 93.73% of US stocks.
- The strongest trend for SNN is in Growth, which has been heading up over the past 179 days.
- SNN ranks lowest in Quality; there it ranks in the 57th percentile.
SNN Stock Summary
- SMITH & NEPHEW PLC's market capitalization of $13,274,449,973 is ahead of 86.94% of US-listed equities.
- With a one year PEG ratio of 2,619.17, SMITH & NEPHEW PLC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 98.93% of US stocks.
- SNN's current price/earnings ratio is 59.53, which is higher than 90.6% of US stocks with positive earnings.
- Stocks with similar financial metrics, market capitalization, and price volatility to SMITH & NEPHEW PLC are SCPL, CCJ, PNR, EBMT, and ATKR.
- Visit SNN's SEC page to see the company's official filings. To visit the company's web site, go to www.smith-nephew.com.
SNN Valuation Summary
- SNN's price/sales ratio is 2.6; this is 18.18% higher than that of the median Healthcare stock.
- SNN's price/earnings ratio has moved up 48.6 over the prior 243 months.
Below are key valuation metrics over time for SNN.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
SNN | 2023-05-23 | 2.6 | 2.6 | 60.9 | 51.1 |
SNN | 2023-05-22 | 2.7 | 2.6 | 62.3 | 52.1 |
SNN | 2023-05-19 | 2.7 | 2.7 | 62.7 | 52.4 |
SNN | 2023-05-18 | 2.7 | 2.7 | 63.2 | 52.7 |
SNN | 2023-05-17 | 2.7 | 2.7 | 64.0 | 53.3 |
SNN | 2023-05-16 | 2.7 | 2.7 | 64.0 | 53.3 |
SNN Growth Metrics
- Its year over year net cashflow from operations growth rate is now at 7.82%.
- Its 5 year net cashflow from operations growth rate is now at 32.37%.
- The year over year net income to common stockholders growth rate now stands at 16.96%.

The table below shows SNN's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-12-31 | 5,215 | 581 | 223 |
2022-06-30 | 5,212 | 1,048 | 524 |
2021-12-31 | 5,212 | 1,048 | 524 |
2021-12-31 | 5,212 | 1,048 | 524 |
2021-06-30 | 4,560.001 | 972.0003 | 448.0001 |
2020-12-31 | 4,560 | 972 | 448 |
SNN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- SNN has a Quality Grade of B, ranking ahead of 77.5% of graded US stocks.
- SNN's asset turnover comes in at 0.445 -- ranking 108th of 186 Medical Equipment stocks.
- HOLX, TTOO, and BIOL are the stocks whose asset turnover ratios are most correlated with SNN.
The table below shows SNN's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-07-03 | 0.445 | 0.694 | 0.050 |
2020-12-31 | 0.449 | 0.694 | 0.051 |
2020-12-31 | 0.449 | 0.694 | 0.051 |
2020-06-27 | 0.556 | 0.740 | 0.146 |
2019-12-31 | 0.592 | 0.740 | 0.174 |
2019-12-31 | 0.592 | 0.740 | 0.174 |
Smith & Nephew PLC ADR (SNN) Company Bio
Smith & Nephew plc, also known as Smith+Nephew, is a British multinational medical equipment manufacturing company headquartered in Watford, England. It is an international producer of advanced wound management products, arthroscopy products, trauma and clinical therapy products, and orthopaedic reconstruction products. Its products are sold in over 100 countries. It is listed on the London Stock Exchange and is a constituent of the FTSE 100 Index. (Source:Wikipedia)
Latest SNN News From Around the Web
Below are the latest news stories about SMITH & NEPHEW PLC that investors may wish to consider to help them evaluate SNN as an investment opportunity.
Smith+Nephew helps personalize robotically-enabled surgery with AI-powered planning software and data visualization platformSmith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today introduces two key products that close the feedback loop for its robotics and digital surgery portfolio – Personalized Planning powered by AI and RI.INSIGHTS Data Visualization Platform. |
Smith+Nephew receives Innovative Technology contract from Vizient for PICO™ Single Use Negative Pressure Wound Therapy SystemsSmith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, today announces its PICO Single Use Negative Pressure Wound Therapy Systems have received an Innovative Technology contract from Vizient, Inc. the nation's largest member-driven health care performance improvement company. The contract was awarded based on the recommendation of the PICO Single Use Negative Pressure Wound Therapy Systems by hospital experts who serve on one of Vizient's member-led councils, and it signifies |
Smith & Nephew's (LON:SN.) Returns On Capital Not Reflecting Well On The BusinessIf we want to find a stock that could multiply over the long term, what are the underlying trends we should look for... |
Smith+Nephew introduces first of its kind handheld digital tensioning device for robotically-enabled total knee arthroplastySmith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today introduced its new CORI™ Digital Tensioner - a purpose built device that lets surgeons measure the ligament tension in a knee prior to cutting bone.1 By enabling a surgeon to quantify joint laxity in the native knee and achieve an optimal ligament tensioning force, the CORI Digital Tensioner helps to reduce variability when balancing the knee in surgery.1-4 This helps make surgical planning more objective versus other |
Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now?Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
SNN Price Returns
1-mo | -4.66% |
3-mo | 6.58% |
6-mo | 12.67% |
1-year | -1.34% |
3-year | -24.98% |
5-year | -9.57% |
YTD | 13.72% |
2022 | -20.26% |
2021 | -16.26% |
2020 | -10.45% |
2019 | 30.78% |
2018 | 8.84% |
SNN Dividends
Ex-Dividend Date | Type | Payout Amount | Change | ||||||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
Continue Researching SNN
Here are a few links from around the web to help you further your research on Smith & Nephew Plc's stock as an investment opportunity:Smith & Nephew Plc (SNN) Stock Price | Nasdaq
Smith & Nephew Plc (SNN) Stock Quote, History and News - Yahoo Finance
Smith & Nephew Plc (SNN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...